Enzo Biochem Stock Up 50% as CEO Steps Down; 2Q Revenue Rises
Enzo Biochem Stock Up 50% as CEO Steps Down; 2Q Revenue Rises
DJ Enzo Biochem Stock Up 50% as CEO Steps Down; 2Q Revenue Rises
By Micah Maidenberg
Enzo Biochem Inc. said it hired an investment bank to evaluate various strategic options as its chief executive plans to step down from the job.
The company focused on molecular diagnostics said founder and CEO Dr. Elazar Rabbani will step down as its top leader but remain a director on the board and take a scientific role when Enzo hires a successor.
Enzo also said it retained health care investment bank Cain Brothers to "evaluate and execute strategic and commercial opportunities."
Shares rose 50% to $4.44 in after-hours trading.
For its latest quarter, Enzo reported net income of $2.3 million, or 5 cents a share, compared with a loss of $7.7 million, or 16 cents a share, for the year-earlier period. Revenue grew to $31.5 million from $19.4 million.
Increased business activity tied to the Covid-19 pandemic helped the company boost revenue, Enzo said. The company has said it provides Covid-19 molecular tests on its Genflex device.
Enzo also said that Gary Huff, the former CEO of LabCorp Diagnostics, will serve as a strategic consultant to its board of directors.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
March 15, 2021 16:36 ET (20:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Enzo Biochem Stock Up 50% as CEO Steps Down; 2Q Revenue Rises
DJ Enzo Biochem股價上漲50%，首席執行官下臺；第二季度收入上升
By Micah Maidenberg
米卡·梅登伯格(Micah Madenberg)著
Enzo Biochem Inc. said it hired an investment bank to evaluate various strategic options as its chief executive plans to step down from the job.
恩佐生物化工公司(Enzo Biochem Inc.)説，在首席執行長計劃辭職之際，該公司聘請了一家投資銀行來評估各種戰略選擇。
The company focused on molecular diagnostics said founder and CEO Dr. Elazar Rabbani will step down as its top leader but remain a director on the board and take a scientific role when Enzo hires a successor.
這家專注於分子診斷的公司表示，創始人兼首席執行官埃拉扎爾·拉巴尼(Elazar Rabbani)博士將辭去最高領導人一職，但仍將擔任董事會董事，在恩佐聘請繼任者時擔任科學角色。
Enzo also said it retained health care investment bank Cain Brothers to "evaluate and execute strategic and commercial opportunities."
恩佐還表示，它聘請了醫療保健投資銀行凱恩兄弟(Cain Brothers)“評估和執行戰略和商業機會。”
Shares rose 50% to $4.44 in after-hours trading.
股價在盤後交易中上漲50%，報4.44美元。
For its latest quarter, Enzo reported net income of $2.3 million, or 5 cents a share, compared with a loss of $7.7 million, or 16 cents a share, for the year-earlier period. Revenue grew to $31.5 million from $19.4 million.
恩佐最近一個季度的淨收益為230萬美元，合每股5美分，而去年同期為虧損770萬美元，合每股虧損16美分。收入從1940萬美元增長到3150萬美元。
Increased business activity tied to the Covid-19 pandemic helped the company boost revenue, Enzo said. The company has said it provides Covid-19 molecular tests on its Genflex device.
恩佐説，與新冠肺炎疫情相關的商業活動增加幫助該公司增加了收入。該公司表示，它在其Genflex設備上提供新冠肺炎分子測試。
Enzo also said that Gary Huff, the former CEO of LabCorp Diagnostics, will serve as a strategic consultant to its board of directors.
恩佐還表示，LabCorp Diagnostics前首席執行官加里·赫夫(Gary Huff)將擔任董事會的戰略顧問。
Write to Micah Maidenberg at micah.maidenberg@wsj.com
寫信給Micah Madenberg，電子郵件：micah.madenberg@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
March 15, 2021 16:36 ET (20:36 GMT)
2021年3月15日美國東部時間16：36(格林尼治標準時間20：36)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧